<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190644</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-011-ST-001</org_study_id>
    <nct_id>NCT01190644</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      What hematopoietic precursor compartments as well as hemoglobin subtypes are affected by
      dosing with Sotatercept (ACE-011)? Based upon a similar prior study with Procrit, Celgene has
      determined that all of these goals could be obtained by an intense 10 patient, Sotatercept
      (ACE-011) pharmacodynamic study, completed by two well known experts in the red cell
      production field.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from
    manufacturer. No alternatives available for use.
  </why_stopped>
  <start_date type="Actual">June 1, 2010</start_date>
  <completion_date type="Actual">September 18, 2012</completion_date>
  <primary_completion_date type="Actual">September 18, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red Blood Cell Mass</measure>
    <time_frame>Up to One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Volume</measure>
    <time_frame>Up to One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Reticulocyte Increase</measure>
    <time_frame>Up to One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hemoglobin</measure>
    <time_frame>Up to One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ACE 011 (Sotatercept)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35mg dose of ACE 011 will be given by subcutaneous injection on Day 1. Up to two additional doses of ACE 011 will be given every 42 days during the treatment period (Day 43 and Day 85)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE 011</intervention_name>
    <description>35 mg subcutaneous (SC) dose on study Day 1, Day 43, Day 85</description>
    <arm_group_label>ACE 011 (Sotatercept)</arm_group_label>
    <other_name>Sotatercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women ≥ 18 years of age.

          2. Histologically confirmed diagnosis of a solid tumor malignancy documented by cytology
             or biopsy.

          3. Presence of metastatic disease.

          4. Hemoglobin value between ≥ 8.0 to &lt; 11.0 g/dL (≥ 80 to &lt; 110 g/L).

          5. ≥ 28 days must have elapsed (prior to pre-dose RBC mass / PV test) since previous
             treatment with erythropoiesis-stimulating agent (including concurrent treatment with
             IV iron).

          6. ≥ 28 days must have elapsed (prior to Day 1) since the last RBC blood transfusion and
             receipt of ≤ 2 units of blood in the past 56 days (prior to Day 1).

          7. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 1.

        Exclusion Criteria:

        At the time of screening, subjects who have any grade ≥ 3 toxicity (according to the
        currently active minor version of NCI CTCAE v4.0, except for the following disease related
        toxicities:

          -  Hematological events - anemia, thrombocytopenia, neutropenia

          -  Non-hematological events - nausea, vomiting, fatigue, muscle or bone/joint pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abderrahmane Laadem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Agnes Healthcare</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg Cancer Institution at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.</citation>
    <PMID>30337358</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <disposition_first_submitted>January 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 4, 2014</disposition_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Red Blood Cell Mass</keyword>
  <keyword>Plasma Volume</keyword>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

